Abstract:BackgroundWhile immune checkpoint blockade has greatly improved clinical outcomes in diseases such as melanoma, there remains a need for predictive biomarkers to determine who will likely benefit most from which therapy. To date, most biomarkers of response have been identified in the tumors themselves. Biomarkers that could be assessed from peripheral blood would be even more desirable, because of ease of access and reproducibility of sampling.MethodsWe used mass cytometry (CyTOF) to comprehensively profile peripheral blood of melanoma patients, in order to find predictive biomarkers of response to anti-CTLA-4 or anti-PD-1 therapy. Using a panel of ~ 40 surface and intracellular markers, we performed in-depth phenotypic and functional immune profiling to identify potential predictive biomarker candidates.ResultsImmune profiling of baseline peripheral blood samples using CyTOF revealed that anti-CTLA-4 and anti-PD-1 therapies have distinct sets of candidate biomarkers. The distribution of CD4+ and CD8+ memory/non-memory cells and other memory subsets was different between responders and non-responders to anti-CTLA-4 therapy. In anti-PD-1 (but not anti-CTLA-4) treated patients, we discovered differences in CD69 and MIP-1β expressing NK cells between responders and non-responders. Finally, multivariate analysis was used to develop a model for the prediction of response.ConclusionsOur results indicate that anti-CTLA-4 and anti-PD-1 have distinct predictive biomarker candidates. CD4+ and CD8+ memory T cell subsets play an important role in response to anti-CTLA-4, and are potential biomarker candidates. For anti-PD-1 therapy, NK cell subsets (but not memory T cell subsets) correlated with clinical response to therapy. These functionally active NK cell subsets likely play a critical role in the anti-tumor response triggered by anti-PD-1.

Emerging biomarkers as predictors to anti-PD1/PD-L1 therapies in advanced melanoma

Research progress of anti-PD-1 / PD-L1 immunotherapy biomarkers

Companion Diagnostics and Predictive Biomarkers for PD-1/PD-L1 Immune Checkpoint Inhibitors Therapy in Malignant Melanoma

Biomarkers Predictive of Survival and Response to Immune Checkpoint Inhibitors in Melanoma

Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges

Mechanistic Insight of Predictive Biomarkers for Antitumor PD‑1/PD‑L1 Blockade: A Paradigm Shift Towards Immunome Evaluation (Review)

Biomarkers of response to PD-1/PD-L1 inhibition

Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients

Deciphering and Overcoming Anti-PD-1 Resistance in Melanoma: A Comprehensive Review of Mechanisms, Biomarker Developments, and Therapeutic Strategies.

Progresses in biomarkers for cancer immunotherapy

Immune checkpoint inhibitors: recent progress and potential biomarkers

PD-1 checkpoint blockade in advanced melanoma patients: NK cells, monocytic subsets and host PD-L1 expression as predictive biomarker candidates

Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors

The current progress of PD-1 / PD-L1 mAb applications in melanoma immunotherapy

Anti-programmed death receptor 1 immunotherapy in melanoma: rationale, evidence and clinical potential

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

CD69 and SBK1 as potential predictors of responses to PD-1/PD-L1 blockade cancer immunotherapy in lung cancer and melanoma

Targeting the PD1/PD-L1 axis in melanoma: Biological rationale, clinical challenges and opportunities

PD-L1 as a biomarker of response to immune-checkpoint inhibitors

Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint Inhibition

Predictive biomarkers for PD-1 and PD-L1 immune checkpoint blockade therapy